This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Epothilone D, R1492
Description: KOS-862 is a polypetide that inhibits cancer cells by the same mechanism as paclitaxel, and preclinical models have shown the compound to be effective against paclitaxel-resistant tumors.
Deal Structure: Under a global development and commercialization agreement between Roche and Kosan, Roche has the worldwide exclusive right to market and sell KOS-862 and epothilone analogs owned by or licensed to Kosan for the treatment of cancer; Kosan will co-develop and has the right to co-promote Kosan/Roche epothilone products in the U.S. for the treatment of cancer.
In October 2007, Kosan Biosciences announced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. The collaborative research, development and commercialization agreement entered into in September 2002 will terminate after a transition period, following which Kosan will reacquire worldwide rights to its epothilone program and have full control of clinical development of KOS-1584 and its other epothilone product candidates going forward.
In June 2008, Bristol-Myers Squibb completed the acquistion of 97.1% of Kosan's shares outstanding.
Pink Sheet Kosan drug fails prostate cancer trial
Pink Sheet Weekly Trademark Review Jan. 10, 2017
Pink Sheet Weekly Trademark Review Oct. 27, 2015
Pink Sheet Pfizer Adds Kosan GI Program To Portfolio
Additional information available to subscribers only: